Related references
Note: Only part of the references are listed.Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review
Alice Zamagni et al.
CLINICAL & EXPERIMENTAL METASTASIS (2022)
Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies
C. Franzese et al.
CLINICAL ONCOLOGY (2021)
Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast
C.J. Tsai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
Yanjun Xu et al.
FRONTIERS IN ONCOLOGY (2021)
Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis
Kangpyo Kim et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Alessio Cortellini et al.
EUROPEAN JOURNAL OF CANCER (2021)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Canadian consensus: oligoprogressive , pseudoprogressive, and oligometastatic non-small-cell lung cancer
S. A. Laurie et al.
CURRENT ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Nicholas D. Klemen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer
Chul Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
SBRT for oligoprogressive oncogene addicted NSCLC
L. Basler et al.
LUNG CANCER (2017)
Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
Bo Qiu et al.
CLINICAL LUNG CANCER (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
Radiation to Oligoprogessive Sites of Disease Can Prolong the Duration of Response to Immune Checkpoint Inhibitors in Patients With Metastatic Non-Small Cell Lung Cancer
T. J. Bledsoe et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Meghan Campo et al.
ONCOLOGIST (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Drug rechallenge and treatment beyond progression-implications for drug resistance
Elizabeth A. Kuczynski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
The therapeutic promise of the cancer stem cell concept
Natasha Y. Frank et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Share Paper
